HTA Barriers for Conditional Approval Drugs
ConclusionsOverall, conditionally approved drugs likely face increased barriers at the HTA level. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 23, 2023 Category: Health Management Source Type: research
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
DiscussionAlthough (mild) AEFI were demonstrated for all five studied vaccines, only a quarter of reviewed studies accounted for these, mostly in an incomplete and inaccurate manner. We provide guidance on which methods to use to better quantify the impact of AEFI on both costs and health outcomes. Policymakers should be aware that the impact of AEFI on cost-effectiveness is likely to be underestimated in the majority of economic evaluations. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 21, 2023 Category: Health Management Source Type: research
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
AbstractThe National Institute for Health and Care Excellence (NICE) invited the manufacturer (Roche) of pralsetinib (Gavreto®), as part of the single technology appraisal (STA) process, to submit evidence for the clinical effectiveness and cost effectiveness of pralsetinib for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small-cell lung cancer (NSCLC) not previously treated with aRET inhibitor. Kleijnen Systematic Reviews Ltd, in collaboration with University Medical Center Groningen, was commissioned to act as the independent Evidence Review Group (ERG). This pap...
Source: PharmacoEconomics - February 9, 2023 Category: Health Management Source Type: research
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
ConclusionsAnti-osteoporosis drugs and nutritional supplements are generally cost effective in men with osteoporosis. Screening strategies and post-fracture care programs also showed economic benefits for men. Cost-effectiveness and intervention thresholds were generally similar in studies conducted in both men and women, with slightly greater incremental cost-effectiveness ratios in men. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 4, 2023 Category: Health Management Source Type: research
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis
ConclusionsThe cost effectiveness of difelikefalin in a range of scenarios could make it an important pharmacotherapy to address the high burden of disease and unmet need for treatments associated with CKD-aP in the UK. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 3, 2023 Category: Health Management Source Type: research
Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study
ConclusionThese 12 value attributes were identified for the development of a VAF to support health technologies ’ value assessment and coverage policymaking in China. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 2, 2023 Category: Health Management Source Type: research
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses
ConclusionOur estimates of informal care costs facilitate including informal care costs in CEAs of life-extending healthcare interventions. Including these costs may influence decisions as it leads to reranking of life-extending interventions compared with interventions improving quality of life. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 1, 2023 Category: Health Management Source Type: research
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
AbstractThe National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca®), as part of the Single Technology Appraisal process, to submit evidence for the clinical effectiveness and cost effectiveness of filgotinib for treating moderately to severely active ulcerative colitis in adults who have had an inadequate response, loss of response or were intolerant to a previous biologic agent or conventional therapy. Kleijnen Systematic Reviews Ltd, in collaboration with Maastricht University Medical Centre+, was commissioned to act as the independent Evidence Review Group. This ...
Source: PharmacoEconomics - February 1, 2023 Category: Health Management Source Type: research
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia
DiscussionThis work develops a value set for the EQ-5D-5L in Australia, and also provides a range of methodological insights which can inform future work using a stand-alone DCE to value health in other countries. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 31, 2023 Category: Health Management Source Type: research
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario
ConclusionsOur analysis suggests that changing the age of the hepatitis B vaccination recommendation from adolescent to newborn is cost effective and mostly a cost-saving strategy. Newborn vaccination may lead to cost and health benefits while aligning with best available evidence and guidance from the World Health Organization. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 28, 2023 Category: Health Management Source Type: research
